У нас вы можете посмотреть бесплатно Clinical Utility of Extended Genotyping или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Presented By: Thomas C Wright, Jr., MD Speaker Biography: Dr. Wright received his Medical Degree from Harvard Medical School; his pathology residency training at Brigham and Women’s Hospital, Boston, Massachusetts, and his fellowship in OB/Gyn Pathology at Columbia University. Dr. Wright served as the Director of the Division of Gynecologic, Perinatal, and Cytologic Pathology at Columbia University Medical Center and also headed the colposcopy services at New York Presbyterian Hospital for over 15 years. Webinar: Clinical Utility of Extended Genotyping Webinar Abstract: Recently the FDA approved the BD Onclarity™ HPV assay as a test to identify HPV high-risk genotypes in addition to HPV 16 and 18 (i.e., extended genotyping). The Onclarity assay is designed to identify the 14 high-risk HPV genotypes either individually (HPV 16, 18, 31, 45, 51, 52) or as a pooled mixture of two to three genotypes (HPV 33/58, 35/39/68, 56/59/66). Because different HPV genotypes are associated with different risks of CIN 3, the use of extended genotyping offers a useful tool when following the “risk-based” management strategy recently adopted by the American Society of Colposcopy and Cervical Pathology (ASCCP). Earn PACE Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/ms/webinar/c...) 2. Watch the webinar on YouTube or on the LabRoots Website https://www.labroots.com/ms/webinar/c...) 3. Click Here to get your PACE credits (Expiration date: October 07, 2022): (https://www.labroots.com/credit/pace-...)